糖尿病基础知识英文概要课件.ppt

1、Diabetes Mellitus,Dr. Rasha Salama PhD Public Health, Suez Canal University, Egypt Diabetes MSc, Cardiff University, United Kingdom,Diabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. The t

2、erm diabetes mellitus describes a metabolic disorder of multiple aetiology characterized by chronic hyperglycaemia with disturbances of carbohydrate, fat and protein metabolism resulting from defects in insulin secretion, insulin action, or both.The effects of diabetes mellitus include longterm dama

3、ge, dysfunction and failure of various organs.,What is diabetes?,Diabetes mellitus may present with characteristic symptoms such as thirst, polyuria, blurring of vision, and weight loss. In its most severe forms, ketoacidosis or a nonketotic hyperosmolar state may develop and lead to stupor, coma an

4、d, in absence of effective treatment, death. Often symptoms are not severe, or may be absent, and consequently hyperglycaemia sufficient to cause pathological and functional changes may be present for a long time before the diagnosis is made.,Diabetes,The longterm effects of diabetes mellitus includ

5、e progressive development of the specific complications of retinopathy with potential blindness, nephropathy that may lead to renal failure, and/or neuropathy with risk of foot ulcers, amputation, Charcot joints, and features of autonomic dysfunction, including sexual dysfunction. People with diabet

6、es are at increased risk of cardiovascular, peripheral vascular and cerebrovascular disease.,Diabetes Long-term Effects,The development of diabetes is projected to reach pandemic proportions over the next10-20 years. International Diabetes Federation (IDF) data indicate that by the year 2025, the nu

7、mber of people affected will reach 333 million 90% of these people will have Type 2 diabetes.In most Western societies, the overall prevalence has reached 4-6%, and is as high as 10-12% among 60-70-year-old people.The annual health costs caused by diabetes and its complications account for around 6-

8、12% of all health-care expenditure.,Burden of Diabetes,Type 1 Diabetes Mellitus Type 2 Diabetes Mellitus Gestational Diabetes Other types: LADA ( MODY (maturity-onset diabetes of youth) Secondary Diabetes Mellitus,Types of Diabetes,Was previously called insulin-dependent diabetes mellitus (IDDM) or

9、juvenile-onset diabetes. Type 1 diabetes develops when the bodys immune system destroys pancreatic beta cells, the only cells in the body that make the hormone insulin that regulates blood glucose. This form of diabetes usually strikes children and young adults, although disease onset can occur at a

10、ny age. Type 1 diabetes may account for 5% to 10% of all diagnosed cases of diabetes. Risk factors for type 1 diabetes may include autoimmune, genetic, and environmental factors.,Type 1 diabetes,Was previously called non-insulin-dependent diabetes mellitus (NIDDM) or adult-onset diabetes. Type 2 dia

11、betes may account for about 90% to 95% of all diagnosed cases of diabetes. It usually begins as insulin resistance, a disorder in which the cells do not use insulin properly. As the need for insulin rises, the pancreas gradually loses its ability to produce insulin. Type 2 diabetes is associated wit

12、h older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity. African Americans, Hispanic/Latino Americans, American Indians, and some Asian Americans and Native Hawaiians or Other Pacific Islanders are at par

13、ticularly high risk for type 2 diabetes. Type 2 diabetes is increasingly being diagnosed in children and adolescents.,Type 2 diabetes,A form of glucose intolerance that is diagnosed in some women during pregnancy. Gestational diabetes occurs more frequently among African Americans, Hispanic/Latino A

14、mericans, and American Indians. It is also more common among obese women and women with a family history of diabetes. During pregnancy, gestational diabetes requires treatment to normalize maternal blood glucose levels to avoid complications in the infant. After pregnancy, 5% to 10% of women with ge

15、stational diabetes are found to have type 2 diabetes. Women who have had gestational diabetes have a 20% to 50% chance of developing diabetes in the next 5-10 years.,Gestational diabetes,Other specific types of diabetes result from specific genetic conditions (such as maturity-onset diabetes of yout

16、h), surgery, drugs, malnutrition, infections, and other illnesses. Such types of diabetes may account for 1% to 5% of all diagnosed cases of diabetes.,Other types of DM,Latent Autoimmune Diabetes in Adults (LADA) is a form of autoimmune (type 1 diabetes) which is diagnosed in individuals who are old

17、er than the usual age of onset of type 1 diabetes. Alternate terms that have been used for “LADA“ include Late-onset Autoimmune Diabetes of Adulthood, “Slow Onset Type 1“ diabetes, and sometimes also “Type 1.5 Often, patients with LADA are mistakenly thought to have type 2 diabetes, based on their a

18、ge at the time of diagnosis.,LADA,LADA (cont.),About 80% of adults apparently with recently diagnosed Type 2 diabetes but with GAD auto-antibodies (i.e. LADA) progress to insulin requirement within 6 years.The potential value of identifying this group at high risk of progression to insulin dependenc

19、e includes: the avoidance of using metformin treatment the early introduction of insulin therapy,LADA (cont.),MODY Maturity Onset Diabetes of the YoungMODY is a monogenic form of diabetes with an autosomal dominant mode of inheritance: Mutations in any one of several transcription factors or in the

20、enzyme glucokinase lead to insufficient insulin release from pancreatic -cells, causing MODY. Different subtypes of MODY are identified based on the mutated gene.Originally, diagnosis of MODY was based on presence of non-ketotic hyperglycemia in adolescents or young adults in conjunction with a fami

21、ly history of diabetes.However, genetic testing has shown that MODY can occur at any age and that a family history of diabetes is not always obvious.,MODY,MODY (cont.),Within MODY, the different subtypes can essentially be divided into 2 distinct groups: glucokinase MODY and transcription factor MOD

22、Y, distinguished by characteristic phenotypic features and pattern on oral glucose tolerance testing. Glucokinase MODY requires no treatment, while transcription factor MODY (i.e. Hepatocyte nuclear factor -1alpha) requires low-dose sulfonylurea therapy and PNDM (caused by Kir6.2 mutation) requires

23、high-dose sulfonylurea therapy.,MODY (cont.),Secondary causes of Diabetes mellitus include: Acromegaly, Cushing syndrome, Thyrotoxicosis, Pheochromocytoma Chronic pancreatitis, Cancer Drug induced hyperglycemia: Atypical Antipsychotics - Alter receptor binding characteristics, leading to increased i

24、nsulin resistance. Beta-blockers - Inhibit insulin secretion. Calcium Channel Blockers - Inhibits secretion of insulin by interfering with cytosolic calcium release. Corticosteroids - Cause peripheral insulin resistance and gluconeogensis. Fluoroquinolones - Inhibits insulin secretion by blocking AT

25、P sensitive potassium channels. Naicin - They cause increased insulin resistance due to increased free fatty acid mobilization. Phenothiazines - Inhibit insulin secretion. Protease Inhibitors - Inhibit the conversion of proinsulin to insulin. Thiazide Diuretics - Inhibit insulin secretion due to hyp

26、okalemia. They also cause increased insulin resistance due to increased free fatty acid mobilization.,Secondary DM,Prediabetes is a term used to distinguish people who are at increased risk of developing diabetes. People with prediabetes have impaired fasting glucose (IFG) or impaired glucose tolera

27、nce (IGT). Some people may have both IFG and IGT. IFG is a condition in which the fasting blood sugar level is elevated (100 to 125 milligrams per decilitre or mg/dL) after an overnight fast but is not high enough to be classified as diabetes. IGT is a condition in which the blood sugar level is ele

28、vated (140 to 199 mg/dL after a 2-hour oral glucose tolerance test), but is not high enough to be classified as diabetes.,Prediabetes: Impaired glucose tolerance and impaired fasting glucose,Progression to diabetes among those with prediabetes is not inevitable. Studies suggest that weight loss and

29、increased physical activity among people with prediabetes prevent or delay diabetes and may return blood glucose levels to normal. People with prediabetes are already at increased risk for other adverse health outcomes such as heart disease and stroke.,Prediabetes: Impaired glucose tolerance and imp

30、aired fasting glucose (cont.),Diagnosis of Diabetes Mellitus,Values of Diagnosis of Diabetes Mellitus,Research studies have found that lifestyle changes can prevent or delay the onset of type 2 diabetes among high-risk adults. These studies included people with IGT and other high-risk characteristic

31、s for developing diabetes.Lifestyle interventions included diet and moderate-intensity physical activity (such as walking for 2 1/2 hours each week). In the Diabetes Prevention Program, a large prevention study of people at high risk for diabetes, the development of diabetes was reduced 58% over 3 y

32、ears.,Prevention or delay of diabetes: Life style modification,Studies have shown that medications have been successful in preventing diabetes in some population groups. In the Diabetes Prevention Program, people treated with the drug metformin reduced their risk of developing diabetes by 31% over 3

33、 years. Treatment with metformin was most effective among younger, heavier people (those 25-40 years of age who were 50 to 80 pounds overweight) and less effective among older people and people who were not as overweight. Similarly, in the STOP-NIDDM Trial, treatment of people with IGT with the drug

34、 acarbose reduced the risk of developing diabetes by 25% over 3 years. Other medication studies are ongoing. In addition to preventing progression from IGT to diabetes, both lifestyle changes and medication have also been shown to increase the probability of reverting from IGT to normal glucose tole

35、rance.,Prevention or delay of diabetes: Medications,Management of Diabetes Mellitus,The major components of the treatment of diabetes are:,Management of DM,Diet is a basic part of management in every case. Treatment cannot be effective unless adequate attention is given to ensuring appropriate nutri

36、tion.Dietary treatment should aim at: ensuring weight control providing nutritional requirements allowing good glycaemic control with blood glucose levels as close to normal as possible correcting any associated blood lipid abnormalities,A. Diet,The following principles are recommended as dietary gu

37、idelines for people with diabetes:Dietary fat should provide 25-35% of total intake of calories but saturated fat intake should not exceed 10% of total energy. Cholesterol consumption should be restricted and limited to 300 mg or less daily.Protein intake can range between 10-15% total energy (0.8-1

38、 g/kg of desirable body weight). Requirements increase for children and during pregnancy. Protein should be derived from both animal and vegetable sources.Carbohydrates provide 50-60% of total caloric content of the diet. Carbohydrates should be complex and high in fibre.Excessive salt intake is to

39、be avoided. It should be particularly restricted in people with hypertension and those with nephropathy.,A. Diet (cont.),Physical activity promotes weight reduction and improves insulin sensitivity, thus lowering blood glucose levels.Together with dietary treatment, a programme of regular physical a

40、ctivity and exercise should be considered for each person. Such a programme must be tailored to the individuals health status and fitness. People should, however, be educated about the potential risk of hypoglycaemia and how to avoid it.,Exercise,There are currently four classes of oral anti-diabeti

41、c agents:i. Biguanides ii. Insulin Secretagogues Sulphonylureas iii. Insulin Secretagogues Non-sulphonylureas iv. -glucosidase inhibitors v. Thiazolidinediones (TZDs),B. Oral Anti-Diabetic Agents,If glycaemic control is not achieved (HbA1c 6.5% and/or; FPG 7.0 mmol/L or; RPG 11.0mmol/L) with lifesty

42、le modification within 1 3 months, ORAL ANTI-DIABETIC AGENT should be initiated.In the presence of marked hyperglycaemia in newly diagnosed symptomatic type 2 diabetes (HbA1c 8%, FPG 11.1 mmol/L, or RPG 14 mmol/L), oral anti-diabetic agents can be considered at the outset together with lifestyle mod

43、ification.,B.1 Oral Agent Monotherapy,As first line therapy:Obese type 2 patients, consider use of metformin, acarbose or TZD.Non-obese type 2 patients, consider the use of metformin or insulin secretagoguesMetformin is the drug of choice in overweight/obese patients. TZDs and acarbose are acceptabl

44、e alternatives in those who are intolerant to metformin.If monotherapy fails, a combination of TZDs, acarbose and metformin is recommended. If targets are still not achieved, insulin secretagogues may be added,B.1 Oral Agent Monotherapy (cont.),Combination oral agents is indicated in:Newly diagnosed

45、 symptomatic patients with HbA1c 10Patients who are not reaching targets after 3 months on monotherapy,B.2 Combination Oral Agents,If targets have not been reached after optimal dose of combination therapy for 3 months, consider adding intermediate-acting/long-acting insulin (BIDS).Combination of in

46、sulin+ oral anti-diabetic agents (BIDS) has been shown to improve glycaemic control in those not achieving target despite maximal combination oral anti-diabetic agents.Combining insulin and the following oral anti-diabetic agents has been shown to be effective in people with type 2 diabetes: Biguani

47、de (metformin) Insulin secretagogues (sulphonylureas) Insulin sensitizers (TZDs)(the combination of a TZD plus insulin is not an approved indication) -glucosidase inhibitor (acarbose)Insulin dose can be increased until target FPG is achieved.,B.3 Combination Oral Agents and Insulin,Diabetes Manageme

48、nt Algorithm,Oral Hypoglycaemic Medications,In elderly non-obese patients, short acting insulin secretagogues can be started but long acting Sulphonylureas are to be avoided. Renal function should be monitored.Oral anti-diabetic agent s are not recommended for diabetes in pregnancyOral anti-diabetic

49、 agents are usually not the first line therapy in diabetes diagnosed during stress, such as infections. Insulin therapy is recommended for both the aboveTargets for control are applicable for all age groups. However, in patients with co-morbidities, targets are individualizedWhen indicated, start wi

50、th a minimal dose of oral anti-diabetic agent, while reemphasizing diet and physical activity. An appropriate duration of time (2-16 weeks depending on agents used) between increments should be given to allow achievement of steady state blood glucose control,General Guidelines for Use of Oral Anti-Diabetic Agent inDiabetes,